Fundraising net proceeds go to COVID-19 Solidarity Response Fund for WHO

Neutrophil-Targeting Peptides as a Treatment for COVID-19

PEEL Therapeutics is introducing a natural peptide that evolved in newborns to block inflammation as a new therapeutic approach to help with the current COVID-19 pandemic.

Dr. Emily Le, producer of Therapeutic Pipeline for COVID-19 Virtual Meeting, got together with PEEL co-founder and CEO Dr. Joshua Schiffman to learn more about his research and how it can be applied to addressing the complications associated with COVID-19. Among other things, babies and elephants are discussed.

EL: I understand that PEEL Therapeutics is inspired by nature for its approach to pharmaceutical discoveries. You are a co-founder of PEEL Therapeutics. Were you interested in nature as a young boy? Tell us how your interactions with nature helped in the ultimate creation of PEEL Therapeutics.

JS: Since I can remember, I have always been interested in nature. Part of my childhood was spent in rural areas of Connecticut and the wooded New England forests became like a playground to me. We moved to Providence, Rhode Island when I was 8 years old and I spent plenty of time at the zoo marveling at the animals. When I eventually reached college, I became fascinated by Darwin and his theories after taking several animal-behavior courses.

Along with medicine, the role of evolution in functional biology has always been an important focus of mine. Several years ago, we helped with the discovery of extra elephant p53 (EP53) that contributes to cancer resistance in these large and long-lived animals. Together with my co-founder, we knew that we needed to find a way to blend advanced technology with millions of years of elephant evolution to introduce new drugs to impact patient lives. My longstanding interest in animals made PEEL Therapeutics an amazing means to draw on my appreciation of nature and biology, specifically evolution, and combine it with my experience practicing medicine.

EL: There are a lot of scary accounts about how COVID-19 causes fatal blood clots in infected patients. Tell us about your “eureka moment” when you realized that neutrophil extracellular traps (NETs) could be linked to COVID-19-induced blood clots?

JS: Excellent question! Prior to COVID-19, we had been very focused on the role of NETs in sepsis. We had very strong preclinical evidence, published and unpublished, with our academic collaborators that PEEL NTPs lead to remarkable improvement in mice with sepsis. We knew that NTPs naturally inhibit NETs and prevent the multiorgan damage in sepsis due to clotting of the vessels leading to vital organs.

The “eureka moment” came when reports began to be published that: 1) nearly hundred percent of COVID-19 fatalities are due to sepsis with respiratory failure, and 2) that COVID-19 was a disease of microthrombi with coagulopathy throughout the patient’s body. This mirrored exactly the pathophysiology observed in our mice with sepsis, and so we knew at that point that we needed to demonstrate the role of NETs in COVID-19.

After we began our study with colleagues at the University of Utah, we saw that NET levels in COVID-19 patients correlate with disease severity (more NET associate with more severe illness) and we knew that our hunch was correct: NTPs may have an important therapeutic role in the COVID-19 pandemic.

EL: How do you think your inflammatory neutrophil-targeting peptides (NTPs) will stack up against traditional drugs in development like antibodies or small molecules, which typically work by neutralizing COVID-19 from binding to human cells?

JS: We are asked this question often. There will, undoubtedly, be many approaches to fighting COVID-19. At PEEL Therapeutics, our focus continues to be on the innate immune system and what nature has provided in her armamentarium to inhibit inflammation. PEEL NTPs originate from peptides found in the first few days of newborn life and, therefore, we expect the side effects to be minimal compared to other therapeutic approaches now in development. Furthermore, it will be difficult to block every viral particle from entering all cells and therefore inflammation due to an overactive NETosis response is still a patient risk.

PEEL NTPs can work in conjunction with other therapies to limit the endothelial damage, microthrombi, and cytokine storm caused by inappropriate NET release. Targeting the root cause of immunothrombosis through NET prevention, we feel, will be the best approach to stopping the downstream inflammation leading to trouble in COVID-19 patients. Although there will be a role for targeting and modulating cytokine release, we prefer PEEL Therapeutics’ strategy of preventing the NETs that lead to the inflammation in the first place.

EL: Do you take excursions to far away ecosystems to get inspired for your next discovery?

JS: I wish there was time these days to take excursions. Most of my travels involve literature searches and trying to stay on top of the latest evolution and animal-focused articles. Reading about the “super powers” and biological adaptations of animals makes me feel like a kid in a candy store. I let my mind wander and think how these nature-based discoveries can be used as the next drug to develop to help people – how have the animals already solved human disease. I love it! 

EL: Do you partner with ecological organizations and NGOs to promote your philosophical ideals?

JS: We have not formally partnered with ecological organization or NGOs, although we have given several talks to politicians and government officials to promote the work we’re doing and the importance of studying nature. We also have ties through our academic partners with the Kenya Wildlife Service where our work on making new medicines from what we learned about elephants is very helpful for their conservation efforts. Finally, we have developed a very strong relationship with Closer to Cure Foundation after receiving award funding. We’re working closely with CTCF on awareness and fundraising efforts for their non-profit organization that promotes research that translates evolutionary biology into medicines for patients.

EL: What do you want the Bioinsider attendees to gain from your talk?

JS: We would like for Bioinsider attendees to appreciate how studying evolutionary biology can inform drug development and design. All of the assets in PEEL Therapeutics originate from an observation made in nature. Evolution provides hundreds of millions of years of research and development on biological solutions to the most challenging problems in health and disease. Specifically, we want Bioinsider attendees to understand the role of NETs in COVID-19 and how our company is introducing a natural peptide that evolved in newborns to block inflammation as a new therapeutic approach to help with the current COVID-19 pandemic.

If you would like to hear Dr. Joshua Schiffman live at the Therapeutic Pipeline for COVID-19 Virtual Meeting, register today with a 30% Discount Promo Code: interview30 (Apply before checkout).

Share on linkedin
Share on twitter
Share on facebook
Share on xing
Share on email

You may also be interested in...

James E. Crowe, Jr., MD,

Director, Vanderbilt Vaccine Center; Professor, Pediatrics and Pathology, Microbiology and Immunology, Ann Scott Carell Chair; Founder, IDBiologics

Dr. Crowe’s laboratory has a broad portfolio of work in the area of viral immunology and antibody sciences, with the goal to discover mechanisms of immunity important to developing new therapeutics and vaccines.

Dr. Crowe received his MD degree from the University of North Carolina at Chapel Hill, where he also completed his pediatrics residency. Following his clinical training, Dr. Crowe received five years of post-doctoral training in the laboratory of Infectious Diseases at the NIH. He completed infectious diseases fellowship training in 1996 at Vanderbilt and has run an independent laboratory at Vanderbilt since that time. He is currently Professor of Pediatrics and of Pathology, Microbiology and Immunology, and the Ann Scott Carell Chair, Vanderbilt University Medical Center. The laboratory’s work has been published in over 300 publications in high-quality science journals including CellScience and Nature, and leading medical journals including the New England Journal of Medicine and JAMA. Dr. Crowe was elected to the National Academy of Medicine in 2014 and the National Academy of Inventors in 2017. He has been the recipient of investigator awards from the March of Dimes, American Society for Microbiology, Pediatric Infectious Diseases Society, and Society for Pediatric Research. He was awarded the Judson Infectious Daland Prize of the American Philosophical Society, the Oswald Avery Award of the IDSA, the E. Mead Johnson Award for Excellence in Pediatrics, the Outstanding Investigator Award of the American Federation for Medical Research, the Norman J. Siegel Award of the American Pediatric Society, the Samuel Rosenthal Prize for Excellence in Academic Pediatrics, the Stanley J. Korsmeyer Award of American Society for Clinical Investigation, the Distinguished Medical Alumnus Award from UNC School of Medicine, Chapel Hill, NC. He is an elected Fellow of AAM, AAAS, ASCI, and AAP, IDSA, APS, and others. His research team was selected as the Best Academic Research Team at the 11th Annual Vaccine Industry Excellence Awards. He was awarded the inaugural 2019 Merck Future Insight Prize, a 1M Euro prize shared with Pardis Sabeti. 

He is the Founder of IDBiologics, Inc., an early-stage biotech company developing human monoclonal antibodies for infectious diseases.

Daniel Chen, MD, PhD

CMO, IGM Bioscience

Daniel S. Chen, MD, PhD, is the Chief Medical Officer for IGM Biosciences, and former Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.  He received a BS degree in Biology from the Massachusetts Institute of Technology (1990), a PhD in Microbiology & Immunology (1996), and MD (1998) from the University of Southern California. His PhD work and publications focused on “Early Events in Coronavirus Infection.”

Daniel completed an Internal Medicine Residency and Medical Oncology Fellowship at Stanford University (2003). He went on to complete a Post-doctoral fellowship with Mark Davis in Immunology, where he was a Howard Hughes Medical Institute Associate. He also ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003-2006. In that time, he studied human anti-cancer immune responses pre- and post-cancer vaccination and cytokine administration to determine why anti-tumor immune responses were not more clinically effective. He received a U19 grant to develop better immunologic tools to interrogate human immune responses and ultimately patented the MHC cellular microarray to detect and functionally characterize antigen-specific T cell states.

He continued as Adjunct Clinical Faculty at Stanford from 2006-2016, where he cared for melanoma patients. At Genentech from 2006-2018, Daniel focused on the clinical development of anti-angiogenic and immune-modulatory targeted therapies in both early and late development, as well as the diagnostic tools to aid their development. This included leading the clinical development for atezolizumab, a PD-L1 inhibitor, from the time the program was in research through IND, Phase I, Phase II, Phase III, to filing and approvals in multiple indications worldwide. At IGM, Daniel focuses on the development of novel engineered multivalent and multispecific therapeutics. He is a reviewer for Nature, Immunity, and Clinical Cancer Research, serves on the Board of Directors for SITC, co-chair of the CRI cancer Immunotherapy consortium, gave the keynote presentation at the AACR NCI EORTC Annual Meeting 2014 and presented at the US Congressional Briefing on Immuno Oncology in 2017. He has continued to publish with academic and industry collaborators in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets Immunology: The Cancer-Immunity Cycle.”

Imre Berger

Founding Director, Max Planck Bristol Centre; Chair in Biochemistry and Chemistry; University of Bristol UK

Imre Berger was trained as a biochemist and synthetic biologist at Leibniz University and Medical School (MHH) in Hannover (Germany), at MIT (Cambridge, USA), and at ETH Zurich (Switzerland). Imre’s team develops enabling methods for DNA delivery and genome engineering, engineers synthetic vaccines and nanosensors and researches the structure and mechanism of multiprotein complexes in human health and disease. After Group Leader posts at ETH (2005) and EMBL (2007), Berger joined Bristol as Full Professor of Biochemistry (2014) with a joint appointment in Chemistry (2019). He is Founding Director of the Max Planck Centre for Minimal Biology in Bristol, Director of the BBSRC/EPSRC research center for synthetic biology BrisSynBio and Co-director of the Bristol Biodesign Institute BBI.

Imre Berger holds international patents for DNA and protein technologies, co-founded three biotech companies, and received numerous distinctions, notably the Swiss Technology Award, the W.A. DeVigier Foundation Award, and a Wellcome Trust Senior Investigator Award for his innovative research. Since 2019, he is an Investigator of the European Research Council (ERC).

Prof. Berger has participated in leading roles in numerous European Commission (EC) projects, including the pan-European structural biology infrastructure INSTRUCT. He has been Coordinator of the EC FP7 HEALTH ComplexINC project enhancing production tools for complex biologics in academic and industrial R&D (2011-2016) and is partner in the EPSRC funded Innovative Future Vaccine Manufacturing Research Hub.

Sina Bavari, PhD

CSO, Edge BioInnovation Consulting and Management; former CSO, Scientific Director US Army Medical Research Institute of Infectious Diseases (USAMRIID)

Dr. Sina Bavari is the co-founder of Healion Bio. He is one of the lead (non-gov) scientific adviser to the World Health Organization on SARSCoV-2. He has spent over 30 years developing rapid response diagnostics, prophylaxis, therapeutics, and vaccines for some of the world’s deadliest infectious diseases. Prior to co-founding Healion Bio, Dr. Bavari founded Edge BioInnovation Consulting and Mgt. and was the Chief Scientific Officer and Scientific Director at USAMRIID (US Army Research Institute of Infectious Diseases), where he spent over twenty years leading the discovery and development of vaccines, therapeutics, and diagnostics or diseases such as SARS and MERS CoVs, Ebola, Marburg, Zika, Smallpox, Sudan, Nipah, alpha viruses, Anthrax and many others. He has worked extensively with the FDA to successfully develop clinically proven countermeasures for many so-called envelope viruses like SARS-CoV-2. Dr. Bavari has contributed to ~20 drug development candidates such as Remdesivir, 30 patents, and many IND filings. He has trained over 70 scientists and managed over 500 scientists and supporting staff. His work has resulted in over 350 publications in many of the leading scientific journals including Nature, Nature Medicine, Cell, Cell Hosts, New England Journal of Medicine and many others. He has degrees from USC, and the University of Nebraska where he received his PhD in Immunotoxicology and Pharmaceutical Science.

Therapeutics Pipeline for COVID-19

Get the latest updates, interviews and receive special offers

Pre-register Today!

Ralph Rogers, MD

Assistant Professor of Medicine, Clinician Educator, Infectious Diseases, Warren Alpert Medical School of Brown University

Ralph Rogers, MD is an infectious disease specialist at the Lifespan Cancer Institute. He earned his medical degree from The Warren Alpert Medical School of Brown University where he also completed his residency and fellowship in infectious diseases. Dr. Rogers is Assistant Professor of Medicine, Clinician Educator Division of Infectious Diseases Warren Alpert Medical School of Brown University. He is a member of the Infectious Diseases Society of America (IDSA), the American Society for Microbiology (ASM) and the American Society of Transplantation (AST).

John Sninsky, PhD

Consultant, Translational Sciences

John J. Sninsky, PhD is a translational medicine consultant with deep understanding of diagnostics and diagnostics paired with medicine intervention. John has served in senior management positions in small and large CLIA service laboratories and in vitro diagnostic kit companies including Cetus, Roche Molecular Systems, Celera, Quest and CareDx. He was a member of the pioneering Cetus team that developed and optimized PCR technology for research and diagnostic use; specifically, the virology team developed the HIV, HTLV, HPV, HCV and HBV PCR assays. John put in place a surveillance initiative for viral variants and presented at the first FDA PMA advisory meeting for HIV PCR approval.

Timothy J. O’Leary, MD, PhD

Adjunct Professor, Pathology, University of Maryland School of Medicine; Former Chief Research and Development Officer, Veterans Affairs

Timothy O’Leary, MD, is Adjunct Professor of Pathology at the University of Maryland and served as Chief Research and Development Officer (CRADO) of the Department of Veterans Affairs from 2013-2015. He holds a doctorate in physical chemistry from Stanford University and a medical degree from the University of Michigan.

He is certified in anatomic pathology by the American Board of Pathology and in molecular genetic pathology by the American Board of Pathology and the American Board of Medical Genetics. Prior to his VA service, O’Leary chaired the Department of Cellular Pathology and Genetics at the Armed Forces Institute of Pathology for more than 15 years. He joined VA in 2004 and served as Director of Biomedical Laboratory Research and Development, Director of Clinical Sciences Research and Development, and Deputy CRADO prior to his appointment as CRADO. O’Leary also served as a reserve member of the Public Health Service Commissioned Corps from 1979 to 2010, serving two tours on active duty. His research interests include genomics, proteomics, and ultrasensitive detection of biological toxins. He has served on numerous federal panels and advisory committees, including the Health and Human Services Clinical Laboratory Improvement Advisory Committee and the Food and Drug Administration Hematology and Devices Panel. O’Leary, the holder of four patents, has authored or co-authored more than 190 journal articles and numerous book chapters and technical reports. He is a past president of the Association for Molecular Pathology and served as editor-in-chief for the Journal of Molecular Diagnostics.